V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016443 | 160013324 | 1.78 | 87 | null | 2020-01-30 | 2020-02-10 | Rucaparib | 02 | null | TAZEMETOSTAT | 100961692 |
| 160016444 | 160013325 | null | 68.9 | Palliative (P) | 2019-06-15 | 2020-02-13 | GEMCITABINE | 02 | N | OLAPARIB | 100920605 |
| 160016447 | 160013326 | 1.68 | 19 | Curative (C) | 2018-12-02 | 2018-12-03 | GEMCITABINE | 02 | N | TRIAL | 101003237 |
| 160016451 | 160013327 | 1.3 | 15.9 | null | 2016-09-25 | 2016-09-25 | PEMBROLIZUMAB | 01 | null | IFOSFAMIDE | 101331193 |
| 160016454 | 160013328 | 0 | 39.1 | Disease modification (D) | 2019-01-04 | 2019-04-13 | Etoposide oral | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101601332 |
| 160016457 | 160013329 | 1.67 | 87 | Curative (C) | 2016-08-02 | 2017-12-14 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100492848 |
| 160016462 | 160013330 | 1.74 | 85 | Curative (C) | 2017-03-09 | 2017-03-09 | PEMBROLIZUMAB | 02 | N | NB HRNBL-1 BUMEL MAT | 101660087 |
| 160016467 | 160013331 | 1.6 | 20.7 | null | 2018-01-11 | 2018-05-30 | Ipilimumab | null | null | DOXORUBICIN + IFOSFAMIDE | 100434212 |
| 160016468 | 160013332 | 1.61 | 101 | null | 2017-10-26 | 2017-10-26 | CVP R | 02 | null | BUSULFAN + MELPHALAN | 101166820 |
| 160016469 | 160013333 | null | 89.35 | Palliative (P) | 2017-03-11 | 2017-09-09 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 100651498 |
| 160016477 | 160013334 | 1.82 | 88.7 | null | 2018-08-10 | 2019-05-19 | Temozolomide + RT | null | null | IPILIMUMAB + NIVOLUMAB | 101786150 |
| 160016479 | 160013335 | 1.77 | 64 | Palliative (P) | 2019-06-23 | 2019-06-30 | NB BEACON Dinutuximab, Temozolomide and Topotecan | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 100294636 |
| 160016487 | 160013336 | 1.72 | 60.2 | Curative (C) | 2018-10-15 | 2018-10-16 | IPM | 02 | N | NOT MATCHED | 101511330 |
| 160016488 | 160013337 | 1.66 | 74.6 | null | 2018-03-13 | 2018-05-05 | EW EuroEwing 2012 Arm B VDC | 99 | null | DACARBAZINE + DOXORUBICIN | 100949605 |
| 160016489 | 160013338 | 1.97 | 46.5 | Palliative (P) | 2016-12-24 | 2017-01-19 | GEMCITABINE | 02 | N | TRIAL | 100100749 |
| 160016492 | 160013339 | 1.63 | 69.6 | Palliative (P) | null | null | Niraparib | 02 | null | EW EUROEWING 2012 ARM B VC | 101692118 |
| 160016495 | 160013340 | 1.6 | 96.3 | Palliative (P) | 2017-09-09 | 2017-12-10 | Ipilimumab | 02 | null | CABOZANTINIB | 100755110 |
| 160016502 | 160013342 | 1.76 | 17.4 | Curative (C) | 2021-08-04 | 2021-09-29 | ETOPOSIDE | N | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 101772014 |
| 160016503 | 160013343 | 1.78 | 95.2 | 03 | 2017-03-04 | 2017-03-07 | VAI (Ifos 3g/m2) | 02 | N | NEMO TRIAL | 101759217 |
| 160016510 | 160013344 | 1.76 | 89 | Curative (C) | 2014-04-16 | 2017-12-28 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | N | CARBOPLATIN + ETOPOSIDE | 101787090 |
| 160016516 | 160013345 | 1.64 | 88.1 | 03 | 2014-10-07 | 2016-01-17 | Etoposide oral | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100085188 |
| 160016524 | 160013346 | 1.62 | 111.35 | Curative (C) | 2019-05-06 | 2019-06-18 | Dacarbazine | 02 | N | NB HRNBL-1 COJEC IND COURSE B | 101410906 |
| 160016526 | 160013347 | null | 72 | null | null | null | Pemetrexed | 02 | null | NB HRNBL-1 COJEC IND COURSE B | 101319145 |
| 160016530 | 160013349 | 1.76 | 99.95 | Curative (C) | 2018-01-04 | 2018-06-12 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | DACARBAZINE + GEMCITABINE | 101066328 |
| 160016540 | 160013350 | null | 61.3 | Palliative (P) | 2019-08-29 | 2020-05-01 | Etoposide oral | 01 | N | NOT MATCHED | 101003034 |
| 160016543 | 160013351 | 0 | 135 | Curative (C) | 2019-01-26 | 2019-02-02 | Trial Unspecified | 01 | Y | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100687076 |
| 160016557 | 160013353 | null | 75 | Curative (C) | 2019-02-15 | 2019-02-20 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 100069644 |
| 160016562 | 160013354 | 1.59 | 57 | Curative (C) | 2019-02-28 | 2019-04-03 | NB HRNBL-1 COJEC Ind COURSE B | 01 | N | ETOPOSIDE | 100895540 |
| 160016564 | 160013355 | 1.66 | 58.2 | Curative (C) | 2020-01-24 | 2020-01-31 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 01 | N | VAI | 100599975 |
| 160016568 | 160013356 | 1.73 | 73.75 | null | 2017-09-14 | 2017-09-29 | Irinotecan + Temozolomide | 02 | null | IVA | 100064632 |
| 160016570 | 160013357 | 1.53 | 105 | null | 2016-06-07 | 2017-01-12 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | null | GEMCITABINE | 100711765 |
| 160016572 | 160013358 | 1.71 | 62.3 | null | 2016-12-10 | 2016-12-13 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | null | EW EUROEWING 2012 ARM B VDC/IE | 101496620 |
| 160016573 | 160013359 | 1.67 | 64.1 | null | 2019-11-24 | 2019-11-24 | Olaratumab | 02 | null | CONFIRM TRIAL | 100506796 |
| 160016576 | 160013360 | 1.87 | 60 | null | 2020-01-24 | 2020-01-24 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | DARATUMUMAB | 101269451 |
| 160016581 | 160013361 | 1.69 | 66 | Curative (C) | 2017-01-06 | 2017-01-07 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | FLUOROURACIL + OXALIPLATIN | 101110125 |
| 160016583 | 160013362 | 1.71 | 70.4 | Palliative (P) | 2019-10-26 | 2019-12-21 | MELPHALAN | 02 | null | OLAPARIB | 101370304 |
| 160016584 | 160013363 | 1.56 | null | Curative (C) | null | 2020-02-08 | PEMBROLIZUMAB | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100622382 |
| 160016587 | 160013365 | null | 18 | Adjuvant (A) | 2021-06-15 | 2021-06-22 | EW EuroEwing 2012 Arm B VC | 02 | N | TRIAL | 101439690 |
| 160016589 | 160013367 | 1.91 | 60.1 | Palliative (P) | 2022-01-25 | 2022-01-25 | Doxorubicin + Ifosfamide | 02 | Y | EW EUROEWING 2012 ARM B IE | 100705812 |
| 160016592 | 160013368 | 1.59 | 61.2 | null | 2016-02-05 | 2019-03-05 | EW EuroEwing 2012 Arm B IE | 02 | null | NB LOW/INTERMED RISK GUIDELINES CADO | 101336104 |
| 160016594 | 160013369 | 0 | 10.5 | Curative (C) | 2018-06-30 | 2018-12-29 | CYCLOPHOSPHAMIDE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100251201 |
| 160016596 | 160013370 | null | 104 | null | 2019-05-05 | 2019-09-28 | STS Rhabdo RMS 2005 Vin Cyclo | 2 | null | STS RHABDO RMS 2005 VIN CYCLO | 101238130 |
| 160016597 | 160013371 | 1.83 | 86.2 | null | 2017-03-17 | 2018-05-22 | ETOPOSIDE + IFOSFAMIDE | 01 | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 101291739 |
| 160016598 | 160013372 | 1.81 | 12 | Palliative (P) | 2018-05-04 | 2018-05-04 | PEMBROLIZUMAB | 02 | null | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 101377863 |
| 160016600 | 160013373 | 0 | 38.1 | Palliative (P) | null | 2020-02-13 | GEMCARBO | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100627325 |
| 160016601 | 160013374 | 1.59 | 84 | null | 2017-05-05 | 2017-07-20 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | null | IFOSFAMIDE | 101288706 |
| 160016613 | 160013375 | 1.68 | 55 | Palliative (P) | 2017-06-30 | 2017-07-10 | null | N | N | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 101487963 |
| 160016614 | 160013376 | 0 | 45.7 | Palliative (P) | 2016-04-29 | 2016-10-27 | ATOMIC-MESO TRIAL | N | N | GEMCITABINE | 101439583 |
| 160016624 | 160013377 | 1.49 | 52.3 | null | null | 2017-05-17 | EW Rel rEECur Irinotecan/Temozolomide | null | null | NB HRNBL | 100967509 |
| 160016631 | 160013378 | 1.52 | 71.55 | null | 2017-12-13 | 2018-01-30 | Doxorubicin + Ifosfamide | Y | null | IFOSFAMIDE | 100602223 |